2021 Volume 64 Issue 8 Pages 450-459
We collected HbA1c values and patient clinical information in the Hamamatsu area to investigate the state of diabetic treatment in October 2012. Since that time, several new drugs have been introduced, and target HbA1c values have been proposed. For comparison with 2012 another investigation was performed in October 2019. Study 1: HbA1c in outpatients. In comparison to 2012, the average HbA1c in general clinics was 6.87 % higher, while that in specialized clinics and hospitals was 7.15 % lower. Study 2: Clinical information of type 2 diabetes patients with HbA1c ≥8 %. In comparison to 2012, the average age was 4 years older in general clinics and 2 years older in specialized clinics and hospitals. In both institutions BMI decreased with aging. Similarly to 2012, patients in the higher HbA1c group were younger and had higher BMI values. In specialized clinics and hospitals, insulin therapy decreased. In both institutions the prescription of sulfonylurea decreased. Therapy with dipeptidyl-peptidase 4 inhibitors, sodium/glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists increased in both institutions. These drug therapy changes can be expected to prevent vascular complications without increasing hypoglycemia or weight gain. The treatment of obese diabetes in younger patients, and the prevention of frailty in elderly patients are future issues.
